COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,244 Articles (22,733 medRxiv, 8,511 bioRxiv)

Most recent first Previous |  Page 1851: Articles 18501-18510  | Next

The SARS-CoV-2 Y453F mink variant displays a striking increase in ACE-2 affinity but does not challenge antibody neutralization
Bayarri-Olmos, R., Rosbjerg, A., Johnsen, L. B., Helgstrand, C., Bak-Thomsen, T., Garred, P., Skjoedt, M.-O.
10.1101/2021.01.29.428834 — Posted: 2021-01-29
Association of COVID-19 incidence with objectively and subjectively measured mental health proxies in the Austrian Football League: an epidemiological study
van der Zee-Neuen, A., Seymer, A., Schaffler-Schaden, D., Herfert, J., O Brien, J., Johansson, T., Kutschar, P., Ludwig, S., Stoeggl, T., Keeley, D., Flamm, M., Osterbrink, J.
10.1101/2021.01.27.21250527 — Posted: 2021-01-29
New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19
Chang, S. E., Feng, A., Meng, W., Apostolidis, S., Mack, E., Artandi, M., Barman, L., Bennett, K., Chakraborty, S., Chang, I., Cheung, P., Chinthrajah, S., Dhingra, S., Do, E., Finck, A., Gaano, A., Gessner, R., Giannini, H. M., Gonzalez, J., Greib, S., Guendisch, M., Hsu, A. R., Kuo, A., Manohar, M., Mao, R., Neeli, I., Neubauer, A., Oniyide, O., Powell, A. E., Puri, R., Renz, H., Schapiro, J. M., Weidenbacher, P. A., Wittman, R., Ahuja, N., Chung, H.-R., Jagannathan, P., James, J., Kim, P. S., Meyer, N. J., Nadeau, K. C., Radic, M., Robinson, W. H., Singh, U., Wang, T. T., Wherry, E. J., Skevaki, C., Prak, E. T. L., Utz, P. J.
10.1101/2021.01.27.21250559 — Posted: 2021-01-29 Discussion: Onsite
The successful use of volunteers to enhance NHS Test and Trace contact tracing of in-patients with Covid-19: a Pilot Study
Foster, R., Jones, B., Reynolds, A., Duda, A., Carey, C., Czauderna, J., Westran, A.
10.1101/2021.01.28.21250096 — Posted: 2021-01-29
SARS-CoV-2 antigenemia/viremia masks seroconversion in a COVID-19 patient
Gorgoulis, V. G.
10.1101/2021.01.26.21250561 — Posted: 2021-01-29
The effectiveness of the first dose of BNT162 b 2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence
Chodcik, G., Tene, L., Patalon, T., Gazit, S., Ben-Tov, A., Cohen, D., Muhsen, K.
10.1101/2021.01.27.21250612 — Posted: 2021-01-29 Discussion: Onsite
Sequencing Data of North American SARS-CoV-2 Isolates Shows Widespread Complex Variants
Ford, C. T., Scott, R., Jacob Machado, D., Janies, D.
10.1101/2021.01.27.21250648 — Posted: 2021-01-29
Passing the Test: A model-based analysis of safe school-reopening strategies
Bilinski, A. M., Salomon, J. A., Giardina, J., Ciaranello, A., Fitzpatrick, M.
10.1101/2021.01.27.21250388 — Posted: 2021-01-29
Self-Reported Mask Wearing Greatly Exceeds Directly Observed Use: Urgent Need for Policy Intervention in Kenya
Jakubowski, A., Egger, D., Nekesa, C., Lowe, L., Walker, M., Miguel, E.
10.1101/2021.01.27.21250487 — Posted: 2021-01-29
The prevalence of olfactory dysfunction and its associated factors in patients with COVID-19 infection
Hasan, M. M., Tamanna, N. A., Jamal, M. N., Uddin, M. J.
10.1101/2021.01.27.21250153 — Posted: 2021-01-29

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).